在人类构成性安德罗斯坦受体上,三种拉布丹二甲的活性差异
Mitsuhiro Sekiguchi1, Yui Fujinami1, Keiyu Takado1
1Department of Food Science, Faculty of Bioresources and Environmental Science, Ishikawa Prefectural University, Nonoichi, Ishikawa, Japan.
Bioscience, biotechnology, and biochemistry
|August 14, 2023
概括
像中的13-epimanool这样的天然化合物与人类构成性安德罗斯坦受体 (hCAR) 结合. 这些化合物的轻微结构差异会对药物代谢酶活性产生多种影响.
科学领域:
- 药理学 药理学 是一个学科.
- 自然产品 化学 化学
- 分子生物学分子生物学
背景情况:
- 构成性安德罗斯坦受体 (CAR) 是药物代谢酶的关键调节者.
- 了解与CAR相互作用的自然化合物对于药物开发和食品安全至关重要.
- 是一种常见的草药,含有各种生物活性化合物.
研究的目的:
- 为了研究13-epimanool的相互作用,一种常见的圣的化合物,与人类的CAR (hCAR).
- 探索结构上相似的拉巴丹二基 (manool 和 sclareol) 对hCAR活性的影响.
- 为了确定自然化合物的微妙结构变化如何影响hCAR调节.
主要方法:
- 差分扫描度 (DSF) 用于评估13-epimanool与重组hCAR蛋白的结合.
- 使用露西法酶试验来评估hCAR对不同化合物的功能性活性.
- 对包括manool,13-epimanool和sclareol在内的labdane diterpenoids进行比较分析.
主要成果:
- 发现13-epimanool可以与hCAR结合.
- 曼和斯克拉,其他天然化合物,也与hCAR结合.
- 曼诺尔作为部分激动剂,13-epimanool作为弱部分激动剂,sclareol作为对抗剂,对CAR活性产生差异性影响.
结论:
- 天然化合物,包括来自草药的拉布丹二类化合物,可以与人类的构成性安德罗斯坦受体相互作用.
- 这些化合物之间的微小结构差异也会显著改变它们对hCAR活性的调节效应.
- 这突显了天然产品通过CAR监管来微调药物代谢的潜力.
相关概念视频
Adrenergic Receptors: β Subtype
1.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
The Two-State Receptor Model
2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
2.0K
Adrenergic Receptors: ɑ Subtype
1.6K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.1K
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
888
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
888
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K


